Prognostic Markers for a Better Follow-up in Head and Neck Cancer.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06094985

Enrollment

Registered

2023-10-23

Start date

2014-02-12

Completion date

2026-05-31

Last updated

2024-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Brief summary

To identify tumor specific DNA mutations and aberrations and to follow these in blood over time to predict treatment response/survival and secondly to correlate presence of these markers in blood to pathological parameters (LVI, Pn, WPOI and margins), radiological findings and to tumor stage.

Interventions

GENETICDNA exome sequencing of tumor and blood

A piece from tumor and a blood sample will be collected during surgery. DNA will be extracted and presence of tumor specific mutations/aberrations will be analysed with a DNA exome seq panel. Presence of identified markers will be followed in blood samples with the same panel and these blood samples will be collected in routine follow-up during the first two years. Presence of markers over time in blood will be correlated to outcomes 1-5.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient diagnosed with head and neck cancer * Treatment includes surgery * Consent to participate

Exclusion criteria

* No consent * Age below 18 years * No surgery * No tumor material to sample

Design outcomes

Primary

Measure	Time frame	Description
Recurrence	2 years	Recurrent disease within 2 years after surgery. Is presence of these DNA changes in blood correlated to recurrence?
Survival	2 years	Alive/dead. Is presence of these DNA changes in blood correlated to survival?
Treatment response	6 months	Is presence of these DNA changes in blood correlated to treatment response?

Secondary

Measure	Time frame	Description
Pathological parameters	6 months	Is presence of these DNA changes correlated to pathological parameters (LVI, Pn, WPOI and margins).
Radiological parameters	9 months	Is presence of these DNA markers in blood correlated to PET-findings?
Stage	2 years	If patients are stratified by stage, are there any differences in Outcome 1-5 (please see above)

Countries

Sweden

Contacts

Primary ContactAnders Näsman, MD PhD

anders.nasman@ki.se+46812370000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026